San Diego, CA, Mar 19: Phanes Therapeutics, Inc. (Phanes), a clinical-stage biotechnology company dedicated to innovative oncology drug discovery, announced that it will present three posters from its ongoing Phase 2 clinical trial of spevatamig (PT886), a first-in-class bispecific antibody targeting CLDN18.2 and CD47, at the American Association for Cancer Research (AACR) Annual Meeting, April 17–22, 2026, in San Diego, CA.
All three presentations will be featured in the Phase II and Phase III Clinical Trials Session, highlighting spevatamig’s potential as a novel therapy for patients with advanced gastrointestinal cancers.
Presentation Details:
-
Pharmacokinetics of spevatamig (PT886) in patients with advanced gastrointestinal cancers as monotherapy or combination therapy
-
Date/Time: April 20, 2026 | 2:00–5:00 PM PST
-
Poster Section: 52 | Poster Board: 8 | Abstract #: CT144
-
First Author: Anwaar Saeed, MD, University of Pittsburgh Medical Center
-
-
Reducing nausea and vomiting while maintaining the full potential for efficacy with spevatamig, a CLDN18.2xCD47 bispecific antibody
-
Date/Time: April 20, 2026 | 2:00–5:00 PM PST
-
Poster Section: 52 | Poster Board: 6 | Abstract #: CT142
-
First Author: Michael Overman, MD, University of Texas MD Anderson Cancer Center
-
-
Resolved hematological toxicities associated with anti-CD47 agents using a bispecific design involving an optimized anti-CD47 arm: A clinical proof of concept study
-
Date/Time: April 20, 2026 | 2:00–5:00 PM PST
-
Poster Section: 52 | Poster Board: 7 | Abstract #: CT143
-
First Author: Harshabad Singh, MD, Mass General Brigham
-
Spevatamig represents a first-in-class therapeutic approach, combining CLDN18.2 targeting with CD47 blockade to enhance anti-tumor activity while minimizing hematologic side effects commonly associated with anti-CD47 therapies. The Phase 2 data aim to provide critical insights into pharmacokinetics, tolerability, and safety in gastrointestinal cancer patients, supporting ongoing clinical development.
